BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25409661)

  • 1. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
    Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
    J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
    Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
    Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques.
    Wierda RJ; Rietveld IM; van Eggermond MC; Belien JA; van Zwet EW; Lindeman JH; van den Elsen PJ
    Life Sci; 2015 May; 129():3-9. PubMed ID: 25445221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay.
    Murashima A; Shinjo K; Katsushima K; Onuki T; Kondoh Y; Osada H; Kagaya N; Shin-Ya K; Kimura H; Yoshida M; Murakami S; Kondo Y
    J Biochem; 2019 Jul; 166(1):41-50. PubMed ID: 30690451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
    Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
    J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
    Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
    Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
    Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
    Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
    J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition.
    Egan B; Yuan CC; Craske ML; Labhart P; Guler GD; Arnott D; Maile TM; Busby J; Henry C; Kelly TK; Tindell CA; Jhunjhunwala S; Zhao F; Hatton C; Bryant BM; Classon M; Trojer P
    PLoS One; 2016; 11(11):e0166438. PubMed ID: 27875550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.
    Simard JR; Plant M; Emkey R; Yu V
    Assay Drug Dev Technol; 2013 Apr; 11(3):152-62. PubMed ID: 23409774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.
    Martin KA; Cesaroni M; Denny MF; Lupey LN; Tempera I
    Mol Cell Biol; 2015 Dec; 35(23):3934-44. PubMed ID: 26370511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.